Conclusions: Our findings indicate that the compounds identified in S. dominguensis exhibit dual agonist activity on PPARγ/PPARα and have the potential for the development of new therapeutic agents helpful in diabetes, obesity, or metabolic syndrome. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.